An internal standard for the quantification of lenalidomide
Related Products
Unlabeled Version(s)
14643Lenalidomide
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Lenalidomide-d5

Item No. 22370

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
5-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione-3,3,4,4,5-d5
CAS Number
1227162-34-6
Molecular Formula
C13H8D5N3O3
Formula Weight
264.3
Purity
≥99% deuterated forms (d1-d5)
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: SolubleMethanol: Soluble
SMILES
NC1=C(CN(C2([2H])C(NC(C([2H])([2H])C2([2H])[2H])=O)=O)C3=O)C3=CC=C1
InChi Code
InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)/i4D2,5D2,10D
InChi Key
GOTYRUGSSMKFNF-QTQWIGFBSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $222

    Add

    1 mg

    $399

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Lenalidomide-d5 is intended for use as an internal standard for the quantification of lenalidomide (Item No. 14643) by GC- or LC-MS. Lenalidomide is a derivative of the immunomodulatory compound thalidomide (Item No. 14610).1 It reduces TNF-α production in isolated human peripheral blood mononuclear cells (PBMCs) and whole blood stimulated by LPS from S. minnesota (Item No. 23608; IC50s = 13 and 25 nM, respectively). Lenalidomide has been used as a building block in the synthesis of PROTACs that induce the degradation of Ikaros family zinc finger protein 1 (IKZF1) and IKZF3 in MM.1S multiple myeloma cells.2 Orally administered lenalidomide (250 mg/kg per day) reduces vascularization and total microvascular length in a rat mesenteric window assay.3 Formulations containing lenalidomide have been used in the treatment of myelodysplastic syndrome and multiple myeloma.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Muller, G.W., Chen, R., Huang, S.Y., et al. Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production. Bioorg. Med. Chem. Lett. 9(11), 1625-1630 (1999).

    2. Krönke, J., Udeshi, N.D., Narla, A., et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343(6168), 301-305 (2014).

    3. Dredge, K., Horsfall, R., Robinson, S.P., et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc. Res. 69(1-2), 56-63 (2005).